Krystal Biotech, Inc. KRYS
We take great care to ensure that the data presented and summarized in this overview for Krystal Biotech, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KRYS
View all-
Black Rock Inc. New York, NY3.95MShares$517 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.83MShares$370 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.73MShares$358 Million7.97% of portfolio
-
State Street Corp Boston, MA1.23MShares$161 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA954KShares$125 Million0.03% of portfolio
-
Redmile Group, LLC San Francisco, CA738KShares$96.6 Million13.97% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA688KShares$90.1 Million7.81% of portfolio
-
Geode Capital Management, LLC Boston, MA612KShares$80.2 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL576KShares$75.3 Million0.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX534KShares$69.9 Million0.02% of portfolio
Latest Institutional Activity in KRYS
Top Purchases
Top Sells
About KRYS
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Insider Transactions at KRYS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2025
|
Suma Krishnan President, R&D |
SELL
Open market or private sale
|
Indirect |
25,000
-0.32%
|
$4,425,000
$177.72 P/Share
|
|
Mar 13
2025
|
Suma Krishnan President, R&D |
SELL
Open market or private sale
|
Direct |
25,000
-0.34%
|
$4,425,000
$177.76 P/Share
|
|
Mar 13
2025
|
Krish S Krishnan President and CEO |
SELL
Open market or private sale
|
Indirect |
25,000
-0.34%
|
$4,425,000
$177.76 P/Share
|
|
Mar 13
2025
|
Krish S Krishnan President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-0.32%
|
$4,425,000
$177.72 P/Share
|
|
Feb 28
2025
|
Suma Krishnan President, R&D |
SELL
Payment of exercise price or tax liability
|
Indirect |
21,985
-0.47%
|
$3,935,315
$179.25 P/Share
|
|
Feb 28
2025
|
Suma Krishnan President, R&D |
BUY
Exercise of conversion of derivative security
|
Indirect |
47,500
+1.0%
|
-
|
|
Feb 28
2025
|
Suma Krishnan President, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
13,885
-0.46%
|
$2,485,415
$179.25 P/Share
|
|
Feb 28
2025
|
Suma Krishnan President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+0.99%
|
-
|
|
Feb 28
2025
|
Kathryn Romano Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,786
-14.19%
|
$1,035,694
$179.25 P/Share
|
|
Feb 28
2025
|
Kathryn Romano Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+23.44%
|
-
|
|
Feb 28
2025
|
Krish S Krishnan President and CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
13,885
-0.46%
|
$2,485,415
$179.25 P/Share
|
|
Feb 28
2025
|
Krish S Krishnan President and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
30,000
+0.99%
|
-
|
|
Feb 28
2025
|
Krish S Krishnan President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,985
-0.47%
|
$3,935,315
$179.25 P/Share
|
|
Feb 28
2025
|
Krish S Krishnan President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,500
+1.0%
|
-
|
|
Feb 27
2025
|
Kathryn Romano Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
750
-5.62%
|
$131,250
$175.22 P/Share
|
|
Feb 26
2025
|
Suma Krishnan President, R&D |
SELL
Payment of exercise price or tax liability
|
Indirect |
4,721
-0.3%
|
$830,896
$176.39 P/Share
|
|
Feb 26
2025
|
Suma Krishnan President, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
3,286
-0.22%
|
$578,336
$176.39 P/Share
|
|
Feb 26
2025
|
Kathryn Romano Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,268
-14.52%
|
$399,168
$176.39 P/Share
|
|
Feb 26
2025
|
Krish S Krishnan President and CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
3,286
-0.22%
|
$578,336
$176.39 P/Share
|
|
Feb 26
2025
|
Krish S Krishnan President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,721
-0.31%
|
$830,896
$176.39 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 168K shares |
|---|
| Payment of exercise price or tax liability | 95.8K shares |
|---|---|
| Open market or private sale | 401K shares |
| Bona fide gift | 5K shares |